The current dynamics of the antipsychotic market show domination by atypical antipsychotics, mainly oral agents, but there is also increasing uptake of long-acting injectable (LAI) neuroleptics, which will continue. Oral atypical antipsychotics that were historical blockbusters are now facing intense generic erosion. The best-selling oral antipsychotic Latuda lost exclusivity in February 2023. Generic atypical antipsychotics, such as olanzapine and risperidone, are widely used as first-line treatments. 

This Datamonitor Healthcare report contains a Disease Analysis module.